Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) said on Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended once-weekly Sogroya (somapacitan) for the treatment of growth hormone deficiency in children and adolescents.
Growth hormone deficiency in children can lead to short stature and other growth-related health problems. Current treatment typically requires daily injections of growth hormone, which can be burdensome and affect adherence, especially in children.
The positive CHMP opinion represents a step forward in providing a simpler treatment option for children as young as three years old.
The recommendation was based on data from the phase 3 REAL4 study, which demonstrated the efficacy of once-weekly subcutaneous injection of Sogroya compared to once-daily Norditropin (somatropin). The European Commission will review the opinion, with a final decision expected in the coming months.
Sogroya received approval from the US Food & Drug Administration (FDA) in April 2023. Subject to approval by the European Commission, it is anticipated to be available in some European countries starting in Q4 2023.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval